VRCA Share Price Performance
US$5.57
-49.43 (-89.87%)
86.1% undervalued intrinsic discount
US$40.00
Fair Value
Price US$5.57
AnalystConsensusTarget US$40.00
Fair ValueUS$40.00
Share PriceUS$5.57
86.1% undervalued intrinsic discount
VRCA Community Narratives
AN
Fair Value US$40.00 86.1% undervalued intrinsic discount
Turnaround Plan Will Commercialize YCANTH And Advance Pipeline
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
VRCA Community Fair Values
- AN
Consensus Narrative from 2 AnalystsTurnaround Plan Will Commercialize YCANTH And Advance Pipeline
Key Takeaways Cost reductions and focus on YCANTH commercialization could improve future revenues and net margins, aiding the turnaround plan. New market opportunities and pipeline progress with VP-315 and YCANTH could significantly boost future revenue if successful.US$40.00FV86.1% undervalued intrinsic discount168.30%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative6users have followed this narrativeUpdated narrative
Recent VRCA News & Updates
No updates
Verrica Pharmaceuticals Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -7.13
- Gross Margin
- -56.22%
- Net Profit Margin
- -919.21%
- Debt/Equity Ratio
- -218.7%
Verrica Pharmaceuticals Inc. Competitors
About VRCA
- Founded
- 2013
- Employees
- 71
- CEO
- WebsiteView website
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company’s product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for molluscum contagiosum. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma; and VP-103, a cantharidin-based product candidate for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 13.1%
- 1 Year: 22.8%
- Year to Date: 7.3%
Over the last 7 days, the market has dropped 1.2%, driven by a decline of 4.7% in the Consumer Discretionary sector. As for the longer term, the market has actually risen by 23% in the last year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading